“…Numerous research studies have been conducted regarding the ability of the measure to identify cognitive change in individuals with normal cognition (Andreotti & Hawkins, 2015; Cooley et al, 2015; Duff & Ramezani, 2015; Phillips et al, 2015; Thaler, Hill, Duff, Mold, & Scott, 2015), Mild Cognitive Impairment (MCI; Clark, Hobson, & O’Bryant, 2010; Duff, Hobson, Beglinger, & O’Bryant, 2010; Hobson, Hall, Humphreys-Clark, Schrimsher, & O’Bryant, 2010; Karantzoulis, Novitski, Gold, & Randolph, 2013; O’Mahar et al, 2012), and Alzheimer’s disease (AD; Burton, Enright, O’Connell, Lanting, & Morgan, 2015; Duff et al, 2008; Enright, O’Connell, MacKinnon, & Morgan, 2015; Heyanka, Scott, & Adams, 2015; McDermott & DeFilippis, 2010; Morgan, Linck, Scott, Adams, & Mold, 2010; Schmitt et al, 2010). Despite these efforts, however, there have been few studies examining the RBANS and its association with imaging biomarkers related to AD, such as decreased hippocampal volumes on magnetic resonance imaging (MRI; Choi et al, 2016; Jack et al, 2010), hypometabolism on fluoro-2-deoxyglucose (FDG) positron emission tomography (PET; Frings, Spehl, Hull, & Meyer, 2016; Jagust et al, 2010), and amyloid accumulations on amyloid PET (Beach, Thal, Zanette, Smith, & Buckley, 2016; L.…”